Revenue from ordinary activities fell $4,238,498 to $23,573,050, a decline of 15% against FY25. Profit before tax attributable to owners was $528,472, compared with $5,312,588, and profit after tax attributable to owners was $1,176,626, down $4,075,716 from $5,252,342. Net tangibleAssetsper ordinary security were 0.28 …
Revenue of $10.8 billion was up 15.5%. Normalised EBIT of $1,090.0 million was up 20.6%, with the margin rising to 10.1% from 9.6%, and normalised NPAT of $732.3 million was up 22.3%. Net debt declined to $663.2 million, or 0.57 times normalised EBITDA, and …
The plan follows the recently announced extension of the approximately 3.4 hectare site lease until April 2031, which the company says gives medium-term certainty to develop and operate the Centre. At the end of the extended term, the company may seek a further five-year …
Revenue of about A$4.4 million was up about 40% on Q3 FY26's A$3.2 million and was the highest quarterly revenue of FY26. Group EBITDA was A$710,000, aMarginof about 16%, against a loss of about A$0.3 million in Q3. EBITDA is stated on a consolidated …
Revenue from ordinary operations was $1,432,082, down 11.3% from $1,615,253. The loss after tax attributable to members was $3,751,367, up 0.7% from $3,723,830, and the net loss attributable to members was $3,757,196. Net tangible assets per ordinary security were 1.06 cents, against 1.13 cents. …
Revenue from ordinary activities was $3,446,008, up 42% or $1,012,668 on the prior year, which the company attributes mainly to increased sales from business development activities. Profit attributable to owners was $109,171, up 185%, reversing a loss of $128,795. Net tangible assets per ordinary …
The series included five patients aged 57 to 69, most with other conditions such as diabetes, high blood pressure or obesity, and some with urinary symptoms or erectile dysfunction before surgery. All had cancer that had grown beyond the outer edge of the prostate, …
Optiscan unveiled InVue in June 2024 as a next-generation microscopic imaging device for precision surgery. It is designed to give surgeons cellular-level imaging in the operating environment, so tissue can be assessed in real time while the patient remains in theatre. The company sees …
PALACROS is described as a European research initiative supported by the Horizon Europe programme and the EU Mission on Cancer. It brings together hospitals, researchers, patient organisations and industry partners to investigate innovative treatment approaches and improve care pathways for LAPC, with aims including …
Osteopore has also secured itsSupplychain and logistics network into Thailand through aPartnershipwith DCH Auriga, an Asia-based integrated market management provider specialising in healthcare. Auriga will be Osteopore's market authorisation holder,Importits devices into Thailand and supply hospitals and clinics as directed by Osteopore. Auriga operates …